Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
55
datasets available to search
ShareScore release 0.9.0
Dataset results
55 results for “neurotoxin”
In silico approach for the identification of novel potent antidotes against botulinum neurotoxin serotypes A, B, E, and F.
<p>Botulinum neurotoxins are the most poisonous substances reported and listed in category ‘A’ of biowarfare agent. These neurotoxins cause flaccid paralysis of muscles by inhibiting acetylcholine release at the neuromuscular junction, and leads to death. The light chain (catalytic domain) is responsible for cleavage of SNAREs and inhibition of its activity stops the progress of neuroparalysis. Serotype identification is a time-consuming process; hence development of inhibitor against human botulism causing serotypes will be advantageous. Computer assisted screening approaches have been proved a proficient in silico method in the drug discovery and development. In present study, ligand-based in silico method was applied to identify the “hits” against human intoxicating BoNTs. The study was carried out with thirty-five designed ligands derived from the structure NSC1012 that consist of o-aminobenzoic acid, benzaldehyde and quinolone rings were docked against the catalytic domain of serotype BoNT/A; B; E and F, for the identification of the potent inhibitor. A computational approach used for virtual screening was performed by Molegro Virtual Docker (MVD) and AutoDock software. Analysis of molecular docking of the complex shows a high binding affinity for the target with Moldock score between -139.85 and -88.24 kcal mol-1and AutoDock score ranges between -11.65 to -5.30 kcal mol-1. These molecules could act as potential pan active inhibitors against botulinum neurotoxins. The designed ligands were expected to be less toxic considering the Lipinski, Ghose, Veber and Egan rules with a bioavailability score of 0.56. Therefore, this study provides ‘hits’ that could be further progressed for experimental studies and lead to develop new antidotes for botulism.</p>
Figure 4 in Analysis of amino acids, fatty acids and neurotoxins using gas chromatography-mass spectrometry in four scorpions species inhabiting New Valley Governorate, Egypt
Figure 4. GC-MS chromatogram of Buthacus leptochelys.
Exposure to Neurotoxins as Risk Factors for Amyotrophic Lateral Sclerosis
ClinicalTrials.gov study NCT00339976. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Study to Evaluate Botulinum Neurotoxin Serotype E (EB-001) in Reducing Musculoskeletal Pain in Abdominoplasty
ClinicalTrials.gov study NCT03429556. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Efficacy and Safety Study of Botulinum Neurotoxin A With Rehabilitation Versus Botulinum Neurotoxin A Alone in Treatment of Post-stroke Spasticity
ClinicalTrials.gov study NCT00945295. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Neurotoxin and Physical Therapy
ClinicalTrials.gov study NCT02177617. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Neurotoxin tetrodotoxin TTX withdrawal induced neuronal activity: RNA Pol II is poised for rapid induction of arc and other neuronal VF-IEGs
GEO Series GSE22622. Rattus norvegicus. 9 samples. Type: Expression profiling by array.
Gene expression profile of neurotoxin exposure in rat midbrain dopaminergic neurons
GEO Series GSE92963. Rattus norvegicus. 8 samples. Type: Expression profiling by array.
Gene expression profiling in human nasal epithelial cells (HNEpCs) stimulated with eosinophil-derived neurotoxin (EDN)
GEO Series GSE111634. Homo sapiens. 4 samples. Type: Expression profiling by high throughput sequencing.
A Novel Medical System for Quantitative Diagnosis and Personalized Precision Botulinum Neurotoxin Injection in Chronic Pelvic Pain Management
ClinicalTrials.gov study NCT05062902. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
A Study to Evaluate the Distribution of Botulinum Neurotoxin Type A Administered as Intradermal Injections, Comparing Different Doses, Concentrations, and Delivery Methods
ClinicalTrials.gov study NCT05585398. IPD Sharing: NO. Countries: 1. Publications: 0.
Botulinum Neurotoxin for Children With CP: a Delicate Balance Between Clinical Benefits and Muscular Harm
ClinicalTrials.gov study NCT06991725. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Sarcopenia and Osteopenia in Individuals With Cerebral Palsy and Influences After Botulinum Neurotoxin Type A Injection
ClinicalTrials.gov study NCT05207124. IPD Sharing: NO. Countries: 1. Publications: 0.
Study Assessing Adult Subjects Affected With Upper and/or Lower Limb Spasticity Treated With Botulinum Neurotoxin Type A
ClinicalTrials.gov study NCT04340336. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Pharmacodynamic and Safety of MT10107(Botulinum Type A Neurotoxin) in Comparison to BOTOX®
ClinicalTrials.gov study NCT03796351. IPD Sharing: Not stated. Countries: 1. Publications: 0.
The Strategic Use of Hyaluronic Acid Fillers and Neurotoxin to Influence Gender Perception in Transgender Individuals
ClinicalTrials.gov study NCT04478214. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Telemedicine Follow-up for Patients With Cervical Dystonia Treated With Neurotoxin Injections
ClinicalTrials.gov study NCT03969537. IPD Sharing: NO. Countries: 1. Publications: 0.
A Prospective, Non-Interventional, Single-Centre Study Assessing the Efficacy of a Holistic Upper Face Treatment With Botulinum Neurotoxin A
ClinicalTrials.gov study NCT07374965. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
The Association of Neurotoxin Exposure With Parkinson's Disease and Parkinsonism in World War II Veterans and Other Men
ClinicalTrials.gov study NCT00018577. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study to Assess the Efficacy of Skin Rejuvenation Therapy in Combination With Neurotoxin and Full Facial Filler Treatments
ClinicalTrials.gov study NCT02551562. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.